Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers

Recent introduction of all-oral direct-acting antiviral (DAA) treatment has revolutionized care of patients with chronic hepatitis C virus (HCV) infection. Regrettably, the high cost of DAA treatment is burdensome for healthcare systems and may be prohibitive for some patients who would otherwise be...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutchinson, James A., Weigand, Kilian, Adenugba, Akinbami, Kronenberg, Katharina, Haarer, Jan, Zeman, Florian, Riquelme, Paloma, Hornung, Matthias, Ahrens, Norbert, Schlitt, Hans J., Geissler, Edward K., Werner, Jens M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808305/
https://www.ncbi.nlm.nih.gov/pubmed/29467758
http://dx.doi.org/10.3389/fimmu.2018.00146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808305/
https://www.ncbi.nlm.nih.gov/pubmed/29467758
http://dx.doi.org/10.3389/fimmu.2018.00146

Ejemplares similares